Global Acute Respiratory Distress Syndrome (ARDS) Market Outlook: COVID-19 Associated with ARDS and Emerging Drugs

News provided by

Dec 14, 2020, 09:45 ET

DUBLIN, Dec. 14, 2020 /PRNewswire/ -- The "Acute Respiratory Distress Syndrome (ARDS) Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS), historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU5 (Germany, France, Italy, and United Kingdom) and Japan.

The Acute Respiratory Distress Syndrome (ARDS) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Acute Respiratory Distress Syndrome (ARDS) market size from 2017 to 2030. The report also covers current Acute Respiratory Distress Syndrome (ARDS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Scope of the Report

The report covers the descriptive overview of Acute Respiratory Distress Syndrome (ARDS), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
Comprehensive insight has been provided into the Acute Respiratory Distress Syndrome (ARDS) epidemiology and treatment.
Additionally, an all-inclusive account of both the current and emerging therapies for Acute Respiratory Distress Syndrome (ARDS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
A detailed review of Acute Respiratory Distress Syndrome (ARDS) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Acute Respiratory Distress Syndrome (ARDS) market.

Report Highlights

Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM is anticipated to rise in the forecasted period (2017-2030).
The market for ARDS in the 7MM is projected to rise during the study period (2017-2030).
Dynamic research and developmental activity with 60+ companies in the pipeline at different stages.
In the coming years, Acute Respiratory Distress Syndrome (ARDS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics are working to assess challenges and seek opportunities that could influence Acute Respiratory Distress Syndrome (ARDS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
Major players are involved in developing therapies for Acute Respiratory Distress Syndrome (ARDS). Launch of emerging therapies will significantly impact the Acute Respiratory Distress Syndrome (ARDS) market.
The in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Key Topics Covered:

1 Key Insights

2 Executive Summary

3 Acute Respiratory Distress Syndrome (ARDS): Market Overview at a Glance

4 Acute Respiratory Distress Syndrome (ARDS): Disease Background and Overview

5 Case Reports

6 Epidemiology and Patient Population

7 7MM Epidemiology Analysis

8 United States Epidemiology

9 EU5 Epidemiology

10 Japan Epidemiology

11 Treatment Algorithm, Current Treatment, and Medical Practices

12 Proposed Guidelines for ARDS

13 Unmet Needs

14 Off-Label Therapies for ARDS

15 Emerging Therapies

16 Unknown Status

17 COVID-19 associated with ARDS: Emerging Drugs

18 Discontinued Products

19 Acute Respiratory Distress Syndrome (ARDS): 7MM Market Analysis

20 Attribute Analysis

21 Key Emerging Therapies: Market Forecast Assumptions

22 United States: Market Outlook

23 EU-5 Countries: Market Outlook

24 Japan Market Outlook

25 Access and Reimbursement

26 Market Drivers

27 Market Barriers

28 SWOT Analysis

Companies Mentioned

Ache Laboratorios Farmaceuticos
Alexion Pharmaceuticals
Algernon Pharmaceuticals
Ampio Pharmaceuticals Inc.
Apeiron Biologics
Apeptico Forschung und Entwicklung GmbH
Aqualung Therapeutics Corp.
Athersys
aTyr Pharma
Bioaegis Therapeutics Inc.
Biohaven Pharmaceutical Holding Co. Ltd.
Biomarck Pharmaceuticals
Bioxytran Inc.
Caladrius Biosciences Inc.
Cellenkos Inc
Celularity Inc.; Sorrento Therapeutics Inc.; Lung Biotechnology PBC, a subsidiary of United Therapeutics Corp.
Cerecor Inc.
Chimerix
Cyclacel Pharmaceuticals
CytoDyn
Diffusion Pharmaceuticals Inc.; University of Virginia
Direct Biologics
Eli Lilly and Company
Faron Pharmaceuticals
GEn1E Lifesciences
GlaxoSmithKline
Histocell, S.L.
Hospital to Academy of Military Medical Sciences/Ivy Institute of Stem Cells Co. Ltd
Humanigen, Inc.
Iltoo Pharma
Implicit Bioscience
Kinevant Sciences GmbH/Roivant Sciences
Kiniksa
Kiniksa Pharmaceuticals
Laboratoire francais de Fractionnement et de Biotechnologies
Lamellar Biomedical Ltd.
Lattice Biologics Ltd.
Leading Biosciences Inc.
Mallinckrodt /Novoteris LLC
Mannkind Corp.; Immix Biopharma Inc.
Medicinova Inc.
Merck/Eli Lilly
Meridigen Biotech
Mesoblast Limited
Mylan Laboratories
Navigen pharmaceuticals
NeuroRx/Relief Therapeutics
Noveome Biotherapeutics
Noxopharm Co.
Pharmazz
PhaseBio Pharmaceuticals
Pluristem Therapeutics
Predictive Biotech, of Salt Lake City, a subsidiary of Predictive Technology Group
Quark Pharmaceuticals
Roche Pharma AG
Sage Therapeutics
Theravance Biopharma,
Tiziana
Vanda Pharmaceuticals Inc.; the University of Illinois at Chicago
Veru
Windtree Therapeutics
XORTX Therapeutics
ZyVersa Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/cwxz59

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets